Table 1 Patient demographics and tumor characteristics grouped by originating institution.
Variable | Curie, N = 15 | MSK, N = 20 | Total, N = 35 |
|---|---|---|---|
Age groupa | |||
Pediatric | 10 (66.7%) | 9 (45.0%) | 19 (54.3%) |
Adolescent/Young adult | 5 (33.3%) | 11 (55.0%) | 16 (45.7%) |
Sex | |||
Female | 9 (60.0%) | 9 (45.0%) | 18 (51.4%) |
Male | 6 (40.0%) | 11 (55.0%) | 17 (48.6%) |
Site | |||
Head and neck | 5 (33.3%) | 8 (40.0%) | 13 (37.1%) |
Abdominopelvis | 3 (20.0%) | 4 (20.0%) | 7 (20.0%) |
Extremity | 7 (46.7%) | 6 (30.0%) | 13 (37.1%) |
Thorax | 0 (0.0%) | 2 (10.0%) | 2 (5.7%) |
Histology/Fusion | |||
Fusion-Positive RMS | 8 (53.3%) | 10 (50.0%) | 18 (51.4%) |
Fusion-Negative RMS | 7 (46.7%) | 10 (50.0%) | 17 (48.6%) |
Size | |||
≤5 cm | 7 (47.0%) | 4 (20.0%) | 11 (31%) |
>5 cm | 8 (53.0%) | 16 (80.0%) | 24 (69%) |
N (TNM Classification) | |||
0 | 5 (33%) | 11 (55%) | 16 (46%) |
1 | 10 (77%) | 9 (45%) | 19 (54%) |
M (TNM Classification) | |||
0 | 9 (60%) | 15 (75.0%) | 24 (69%) |
1 | 6 (40%) | 5 (25.0%) | 11 (31%) |
RMS Risk group (COG) | |||
High | 13 (87%) | 12 (60.0%) | 25 (71%) |
Intermediate | 2 (13%) | 7 (35.0%) | 9 (26%) |
Low | 0 (0.0%) | 1 (5.0%) | 1 (3%) |
Relapse site | |||
Local | 6 (42.9%) | 9 (47.4%) | 15 (45.5%) |
Metastatic | 8 (57.1%) | 7 (36.8%) | 15 (45.5%) |
Regional | 0 (0.0%) | 3 (15.8%) | 3 (9.1%) |
NA | 1 | 1 | 2 |
5-year Overall Survival rates [95% IC] | 31% [13–73] | 35% [13–89] | 33% [18–62] |
